Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
VAL
vs
F
FTSE All Share Index
VAL
Over the past 12 months, VAL has outperformed FTSE All Share Index, delivering a return of -74% compared to FTSE All Share Index's 0% growth.
Stocks Performance
VAL vs FTSE All Share Index
Performance Gap
VAL vs FTSE All Share Index
Performance By Year
VAL vs FTSE All Share Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
ValiRx PLC
Glance View
ValiRx Plc is a life science company. The company is headquartered in Nottingham, Nottinghamshire and currently employs 14 full-time employees. The company went IPO on 2000-02-28. The firm provides the scientific, financial, and commercial framework for enabling rapid translation of science into clinical development. The firm selects and incubates novel drug candidates and guides them through an optimized process of development, from pre-clinical studies to clinical and investor-ready assets. Its product pipeline includes VAL201, VAL301, CLX001 and BC201. VAL201 is a short peptide being studied for the treatment of prostate cancer. VAL201 can prevent cancerous cell proliferation (or growth) without interfering with other functions of the androgen receptor or SRC kinase. CLX001 is a peptide in nanoparticle formulation and is designed for precision destruction of cancer cells to avoid excessive side effects.